Hyperacidity, GERD, and ulcers:
Indications for: Ranitidine
Active duodenal or benign gastric ulcer. Maintenance of healing of duodenal or gastric ulcer. Pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome and systemic mastocytosis). GERD. Erosive esophagitis. Maintenance of healing of erosive esophagitis.
>16yrs: Active duodenal ulcer: 150mg twice daily or 300mg once daily after evening meal or at bedtime for up to 8wks; maintenance: 150mg at bedtime. Active benign gastric ulcer, hypersecretory conditions or GERD: 150mg twice daily; max 6g daily in hypersecretory conditions. Maintenance of healing of gastric ulcer: 150mg at bedtime. Limit to 6wks in benign gastric ulcer. Esophagitis: 150mg 4 times daily; reevaluate after 12wks; maintenance of healing of erosive esophagitis: 150mg twice daily. Renal impairment (CrCl <50mL/min): 150mg every 24hrs or more often if needed. Coincide a dose for end of hemodialysis. May give antacids concomitantly.
<1month: not recommended. ≥1month–16yrs: Treatment of duodenal or gastric ulcers: 2–4mg/kg per day in two divided doses; max 300mg/day. Maintenance of healing of duodenal or gastric ulcers: 2–4mg/kg per day once daily; max 150mg/day. GERD, erosive esophagitis: 5–10mg/kg per day usually in two divided doses. Renal impairment (CrCl <50mL/min): reduce dose; see full labeling.
History of acute porphyria: not recommended. Renal impairment: reduce dose. Hepatic dysfunction. Discontinue if hepatic disorders occur. Monitor SGPT if on high-dose IV therapy for ≥5 days. Pregnancy (Cat.B). Nursing mothers.
May increase triazolam, midazolam, glipizide, procainamide levels. May decrease ketoconazole, atazanavir, delaviridine, gefitnib levels. Monitor anticoagulants. May cause false (+) urine protein test with Multistix.
Headache, GI disturbances, jaundice, hepatitis, rash; rare: CNS disturbances, arrhythmias, blurred vision, arthralgia, myalgia, inj site reactions, blood dyscrasias, anaphylaxis, angioneurotic edema, acute interstitial nephritis, bradycardia with rapid administration (IV); increased risk of pneumonia (see full labeling).
Tabs, syrup—contact supplier; Inj single dose (2mL)—10; Multidose (6mL)—1; Premixed (50mL)—24